Application of human interleukin 22 in preparation of marker for liver transplantation rejection reaction

A rejection reaction, human interleukin technology, applied in the field of liver transplantation rejection markers, can solve the problem of lack of IL-22

Inactive Publication Date: 2012-10-17
ARMY MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report that IL-22 (human interleukin 22) participates in the immune response of transplant rejection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human interleukin 22 in preparation of marker for liver transplantation rejection reaction
  • Application of human interleukin 22 in preparation of marker for liver transplantation rejection reaction
  • Application of human interleukin 22 in preparation of marker for liver transplantation rejection reaction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment one animal modeling

[0021] 1. Establishment of orthotopic liver transplantation model in experimental animals and rats

[0022] Male BN (RT1 n ) rats and LEW (RT1 1 ) rats, SPF animals, weighing 220-270 g, were purchased from the Experimental Animal Center of Daping Hospital, Third Military Medical University. Raise them in a constant temperature and clean environment, maintain a 12-hour circadian rhythm, and abide by the principles of experimental animal use and management. The donor and recipient were fasted for 8 hours before the operation, and were not allowed to eat or drink after the operation. The rat liver transplantation rejection model was divided into rejection group and tolerance group, and the rejection group was LEW(RT1 1 ) rats as donor BN (RT1 n ) rats as recipients, tolerance group BN (RT1 n ) rats as donor LEW(RT1 1 ) rats as recipients, 15 pairs in each group. The rat orthotopic liver transplantation animal model was established b...

Embodiment 2

[0033] Example 2 Application of Human Interleukin 22 in the Preparation of Markers of Liver Transplantation Rejection

[0034] 1 Immunohistochemical reaction

[0035] Using IL-17, IL-22 and INF-γ antibodies as working solutions (purchased from Beijing Boaosen Biotechnology Co., Ltd.), immunohistochemical S-P method (purchased from Zhongshan Jinqiao Company) was performed according to the instructions.

[0036] Such as Figure 4 From the immunohistochemical test results shown, it can be seen that the expression of IL-17 and IL-22 in the rejection group was more obvious than that in the tolerance group on the 1st and 3rd day after operation.

[0037]2Western-blot detection

[0038] Primary antibody: IL-17 was purchased from Beijing Biosen, IL-22 was purchased from Santa Cruz, HRP secondary antibody and internal reference primary antibody were purchased from GenScript. The tissue total protein was extracted by the tissue homogenate method, and the loading sample was taken out ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the field of medicine, and especially to an application of human interleukin (IL) 22 in preparation of a marker for a liver transplantation rejection reaction. In liver transplantation, clinical study results show that TH17 related factors of IL-17 and IL-22 are significantly increased in sera of patients after liver transplantation surgeries; compared with IL-17, the IL-17 in liver tissues of patients in a rejection group is significantly increased in the 1st day and the 3rd day after the liver transplantation surgeries, and is gradually reduced in the next 5-7 days, and the IL-22 in liver tissues of patients in a rejection group after the liver transplantation surgeries is significantly increased in the 1st day, and is gradually reduced from the 3rd day, wherein expressions of the IL-17 and the IL-22 of the patients in the rejection group provide statistical significances compared with the tolerance group after the liver transplantation surgeries.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to a marker of liver transplantation rejection. Background technique [0002] Liver transplantation refers to a surgical treatment that implants a healthy liver into the patient's body through surgery, so that the liver function of patients with end-stage liver disease can be well restored. Depending on the location of the donor liver, it can be divided into orthotopic liver transplantation and heterotopic liver transplantation. Orthotopic liver transplantation (OLT) has become a well-established technique in liver surgery and, for many patients with end-stage liver disease, it is the only effective treatment. Despite the successful use of immunosuppressive agents, acute graft rejection, caused by infiltrating lymphocytes, monocytes, and other inflammatory cells, remains one of the major risk factors for early donor injury and post-transplant survival. Studies have shown that IFNγ, which p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
Inventor 张轶倪兵
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap